Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

VEGFR2/CD309 antibody (VEGF Receptor 2) Primary Antibody

VEGFR2 Reactivity: Human BR, ELISA, FACS, IP, WB Host: NSO Cells Monoclonal Ramucirumab unconjugated
Catalog No. ABIN6731006
$360.00
Plus shipping costs $45.00
100 μL
local_shipping Shipping to: United States
Delivery in 7 to 8 Business Days
  • Target
    VEGFR2/CD309 (VEGFR2)
    Antibody Type
    Recombinant Antibody
    Reactivity
    • 335
    • 215
    • 146
    • 17
    • 8
    • 5
    • 3
    • 3
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Human
    Host
    • 317
    • 65
    • 16
    • 2
    • 2
    • 1
    • 1
    NSO Cells
    Clonality
    • 303
    • 101
    Monoclonal
    Conjugate
    • 185
    • 33
    • 21
    • 15
    • 15
    • 13
    • 12
    • 11
    • 11
    • 10
    • 10
    • 10
    • 10
    • 5
    • 5
    • 5
    • 5
    • 5
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This VEGFR2/CD309 antibody is un-conjugated
    Application
    • 213
    • 155
    • 114
    • 102
    • 79
    • 67
    • 43
    • 25
    • 24
    • 15
    • 14
    • 13
    • 9
    • 9
    • 8
    • 4
    • 4
    • 2
    • 1
    Blocking Reagent (BR), ELISA, Flow Cytometry (FACS), Immunoprecipitation (IP), Western Blotting (WB)
    Purpose
    Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D.
    Specificity
    "Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D."
    Characteristics
    "This is a therapeutic antibody derived from Cyramza and designed for research purposes. Ramucirumab, the active ingredient of Cyramza, is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D." Vascular Endothelial Growth Factor (VEGF) Receptor 2 is the key mediator of VEGF induced angiogenesis. Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components, including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and migration of human endothelial cells.
    Purification
    The commercial therapeutic mAb was diluted with sterile PBS to a final 1 mg/ml.  (original drug Cyramza 100 was diluted 1:10)
    Sterility
    Sterile
    Clone
    Ramucirumab
  • Application Notes
    Optimal dilution for a specific application should be determined by user
    Comment

    Ramucirumab is a human IgG1 monoclonal antibody produced in murine (NS0) cells by recombinant DNA technology.

    Protocol
    Research-relevant quantities are available as licence-free consumable as diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    The dilutant is sterile PBS pH 7.4. No preservatives added
    Preservative
    Without preservative
    Handling Advice
    open only under sterile conditions
    Storage
    4 °C,-20 °C
    Storage Comment
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
    Expiry Date
    36 months
  • Target
    VEGFR2/CD309 (VEGFR2)
    Alternative Name
    VEGFR2 (VEGFR2 Antibody Abstract)
    Synonyms
    CD309, FLK1, VEGFR, VEGFR2, 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2, sVEGFR-2, Vegfr-2, FLK-1, flk-1, vegfr-2, KDR, FLK/KDR, flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, wu:fc31a09, fk52c05, flk, kdr, kdra, vegfr2, vegfr4, vegr2, wu:fk52c05, kinase insert domain receptor, kinase insert domain protein receptor, vascular endothelial growth factor receptor kdr-like, kinase insert domain receptor (a type III receptor tyrosine kinase), kinase insert domain receptor like, KDR, Kdr, LOC100136647, kdr, kdrl
    Background
    Synonyms: CD309, FLK1, VEGFR, 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2, sVEGFR2, Vegfr-2, FLK-1, flk-1, vegfr-2, KDR, FLK/KDR, flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, wu:fc31a09
    Molecular Weight
    152 kDa
    Gene ID
    3791
    UniProt
    P35968
    Pathways
    RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling
You are here:
help Support